Hoth Therapeutics, Inc. (HOTH) said that it has signed an agreement with LTS Therapy Systems LLC, to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year.
HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease.
The HT-ALZ prototype development and manufacturing work by LTS will be used to support a future Investigational New Drug Application to initiate clinical trials.
In pre-market, the shares were gaining 45.82 percent to trade at $1.40.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.